NeOnc Technologies (NTHI) announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer, CCO. Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies files to sell 5.71M shares of common stock for holders
- NeOnc Technologies announces global patent portfolio totals 176
- NeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01
- NeOnc Technologies Appoints New President Amid Strategic Moves
- NeOnc Technologies appoints Heshmatpour as President